{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:59:48Z","timestamp":1768906788131,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1038\/s41409-020-0951-0","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T18:02:33Z","timestamp":1590256953000},"page":"1317-1325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT"],"prefix":"10.1038","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9340","authenticated-orcid":false,"given":"Yu","family":"Akahoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-8958","authenticated-orcid":false,"given":"Satoshi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaito","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-0021","authenticated-orcid":false,"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5163-0163","authenticated-orcid":false,"given":"Katsuhiro","family":"Shono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-7112","authenticated-orcid":false,"given":"Souichi","family":"Shiratori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-3395","authenticated-orcid":false,"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"key":"951_CR1","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O\u2019Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396\u2013407.","journal-title":"Blood"},{"key":"951_CR2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460\u20136.","journal-title":"J Clin Oncol"},{"key":"951_CR3","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2013-11-538728","volume":"123","author":"S Mizuta","year":"2014","unstructured":"Mizuta S, Matsuo K, Nishiwaki S, Imai K, Kanamori H, Ohashi K, et al. Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2014;123:2325\u201332.","journal-title":"Blood"},{"key":"951_CR4","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711\u20139.","journal-title":"Blood"},{"key":"951_CR5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","volume":"1","author":"F Ravandi","year":"2016","unstructured":"Ravandi F, Othus M, O\u2019Brien SM, Forman SJ, Ha CS, Wong JYC, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in philadelphia chromosome positive ALL. Blood Adv. 2016;1:250\u20139.","journal-title":"Blood Adv"},{"key":"951_CR6","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.bbmt.2019.08.014","volume":"25","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transpl. 2019;25:2113\u201323.","journal-title":"Biol Blood Marrow Transpl"},{"key":"951_CR7","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bmt.2013.140","volume":"48","author":"H Kanamori","year":"2013","unstructured":"Kanamori H, Mizuta S, Kako S, Kato H, Nishiwaki S, Imai K, et al. Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transpl. 2013;48:1513\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"951_CR8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2013.68","volume":"48","author":"J Tanaka","year":"2013","unstructured":"Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, et al. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow Transpl. 2013;48:1389\u201394.","journal-title":"Bone Marrow Transpl"},{"key":"951_CR9","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156\u201364.","journal-title":"Blood"},{"key":"951_CR10","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","volume":"116","author":"M Mohty","year":"2010","unstructured":"Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439\u201343.","journal-title":"Blood"},{"key":"951_CR11","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJ van Dongen","year":"2015","unstructured":"van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996\u20134009.","journal-title":"Blood"},{"key":"951_CR12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2017009845","volume":"1","author":"M Bruggemann","year":"2017","unstructured":"Bruggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017;1:2456\u201366.","journal-title":"Blood Adv"},{"key":"951_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2015.217","volume":"51","author":"S Nishiwaki","year":"2016","unstructured":"Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transpl. 2016;51:43\u201350.","journal-title":"Bone Marrow Transpl"},{"key":"951_CR14","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, O\u2019Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070\u20137.","journal-title":"Blood"},{"key":"951_CR15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547\u201355.","journal-title":"Lancet Oncol"},{"key":"951_CR16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, Patel K, O\u2019Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504\u20137.","journal-title":"Blood"},{"key":"951_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3\u201310.","journal-title":"Int J Hematol"},{"key":"951_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","volume":"103","author":"J Kanda","year":"2016","unstructured":"Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103:11\u20139.","journal-title":"Int J Hematol"},{"key":"951_CR19","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.leu.2402483","volume":"16","author":"H Yokota","year":"2002","unstructured":"Yokota H, Tsuno NH, Tanaka Y, Fukui T, Kitamura K, Hirai H, et al. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay. Leukemia. 2002;16:1167\u201375.","journal-title":"Leukemia"},{"key":"951_CR20","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","volume":"104","author":"M Towatari","year":"2004","unstructured":"Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004;104:3507\u201312.","journal-title":"Blood"},{"key":"951_CR21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"951_CR22","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825\u20138. 1994","journal-title":"Bone Marrow Transpl"},{"key":"951_CR23","first-page":"250","volume":"28","author":"KM Sullivan","year":"1991","unstructured":"Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250\u20139.","journal-title":"Semin Hematol"},{"key":"951_CR24","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"951_CR25","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.bbmt.2018.06.006","volume":"24","author":"Y Akahoshi","year":"2018","unstructured":"Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, et al. Additional cytogenetic abnormalities with philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era. Biol Blood Marrow Transpl. 2018;24:2009\u201316.","journal-title":"Biol Blood Marrow Transpl"},{"key":"951_CR26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"951_CR27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajh.24933","volume":"93","author":"Y Arai","year":"2018","unstructured":"Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, et al. Improved prognosis with additional medium-dose VP16 to CY\/TBI in allogeneic transplantation for high risk ALL in adults. Am J Hematol. 2018;93:47\u201357.","journal-title":"Am J Hematol"},{"key":"951_CR28","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1080\/10428194.2019.1636986","volume":"60","author":"K Harada","year":"2019","unstructured":"Harada K, Tachibana T, Ohashi K, Ozawa Y, Sawa M, Kondo T, et al. The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation. Leuk Lymphoma. 2019;60:3521\u20138.","journal-title":"Leuk Lymphoma"},{"key":"951_CR29","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.athoracsur.2015.11.024","volume":"101","author":"AD Althouse","year":"2016","unstructured":"Althouse AD. Adjust for multiple comparisons? It\u2019s not that simple. Ann Thorac Surg. 2016;101:1644\u20135.","journal-title":"Ann Thorac Surg"},{"key":"951_CR30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2013.253","volume":"28","author":"V Bachanova","year":"2014","unstructured":"Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28:658\u201365.","journal-title":"Leukemia"},{"key":"951_CR31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ajh.23465","volume":"88","author":"KS Eom","year":"2013","unstructured":"Eom KS, Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013;88:634\u201341.","journal-title":"Am J Hematol"},{"key":"951_CR32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","volume":"100","author":"E Brissot","year":"2015","unstructured":"Brissot E, Labopin M, Beckers MM, Socie G, Rambaldi A, Volin L, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100:392\u20139.","journal-title":"Haematologica"},{"key":"951_CR33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s12185-015-1883-0","volume":"102","author":"S Takashima","year":"2015","unstructured":"Takashima S, Miyamoto T, Kamimura T, Yoshimoto G, Yoshida S, Henzan H, et al. Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosomepositive acute lymphoblastic leukemia. Int J Hematol. 2015;102:689\u201396.","journal-title":"Int J Hematol"},{"key":"951_CR34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cncr.31874","volume":"125","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer. 2019;125:873\u201383.","journal-title":"Cancer"},{"key":"951_CR35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","volume":"35","author":"I Iacobucci","year":"2017","unstructured":"Iacobucci I, Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol. 2017;35:975\u201383.","journal-title":"J Clin Oncol"},{"key":"951_CR36","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","volume":"2","author":"F Ravandi","year":"2018","unstructured":"Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018;2:1356\u201366.","journal-title":"Blood Adv"},{"key":"951_CR37","doi-asserted-by":"crossref","unstructured":"Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, et al. Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 2020. (in press).","DOI":"10.1111\/bjh.16540"},{"key":"951_CR38","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878\u201387.","journal-title":"J Clin Oncol"},{"key":"951_CR39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbmt.2011.07.013","volume":"18","author":"P Chevallier","year":"2012","unstructured":"Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transpl. 2012;18:289\u201394.","journal-title":"Biol Blood Marrow Transpl"},{"key":"951_CR40","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","volume":"21","author":"ML Sorror","year":"2015","unstructured":"Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl. 2015;21:1479\u201387.","journal-title":"Biol Blood Marrow Transpl"},{"key":"951_CR41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344\u201353.","journal-title":"Blood"},{"key":"951_CR42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bmt.2011.131","volume":"47","author":"S Yoshihara","year":"2012","unstructured":"Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transpl. 2012;47:508\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"951_CR43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2018;53:521\u201334.","journal-title":"Bone Marrow Transpl"},{"key":"951_CR44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.24613","volume":"92","author":"H Nakasone","year":"2017","unstructured":"Nakasone H, Fuji S, Yakushijin K, Onizuka M, Shinohara A, Ohashi K, et al. Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. Am J Hematol. 2017;92:171\u20138.","journal-title":"Am J Hematol"},{"key":"951_CR45","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","volume":"27","author":"H Pfeifer","year":"2013","unstructured":"Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27:1254\u201362.","journal-title":"Leukemia"},{"key":"951_CR46","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/cas.14167","volume":"110","author":"Y Akahoshi","year":"2019","unstructured":"Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, et al. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Sci. 2019;110:3255\u201366.","journal-title":"Cancer Sci"},{"key":"951_CR47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2020.01.001","volume":"81","author":"Y Akahoshi","year":"2020","unstructured":"Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, et al. Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic leukemia in the dasatinib era. Exp Hematol. 2020;81:60\u201367.","journal-title":"Exp Hematol"},{"key":"951_CR48","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"S Giebel","year":"2016","unstructured":"Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122:2941\u201351.","journal-title":"Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0951-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0951-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0951-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:18:25Z","timestamp":1684617505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0951-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0951-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}